



At CardioNet:

Investor Relations

1.800.908.7103

investorrelations@cardionet.com

**CardioNet, Inc.
Company Fact Sheet
Mobile Cardiac Outpatient Telemetry™**

Company Overview

CardioNet, a publicly traded company founded in 1999 and based in Pennsylvania, is the first provider of Mobile Cardiac Outpatient Telemetry (MCOT™). The CardioNet system integrates cardiac monitoring, wireless communication, and Internet technologies to offer unprecedented diagnostic information and patient management resources to physicians treating patients with arrhythmias.

This technology offers significant clinical and economic benefits:

- The CardioNet MCOT system enables physicians to quickly diagnose and effectively treat arrhythmias.
- Early diagnosis through mobile cardiac outpatient telemetry reduces the use of unproductive diagnostic tests, repeated ER visits, and hospitalizations that contribute to the rising economic burden on healthcare.
- Early treatment of heart arrhythmias can prevent strokes, heart failure, and other serious complications that can result from undetected arrhythmias.

The company received FDA marketing clearance for its core technology in February 2002, and began serving patients through its first monitoring center, located in Philadelphia. In its first year of operation, the CardioNet Center monitored nearly 3,000 patients. More than 80 percent of the cardiologists and electrophysiologists in its initial service area became regular prescribers.

Today, CardioNet has monitored more than 500,000 patients and service has expanded throughout the continental United States. Additionally, CardioNet has been referenced in numerous clinical papers, including a multi-center, 300 patient randomized trial comparing the efficacy of CardioNet's technology with Loop event monitoring, completed by principal investigator Steven A. Rothman, M.D., Mainline Arrhythmia and Cardiology Consultants, Wynnewood, PA. In this trial, CardioNet was proven to be nearly three times more effective than Loop event monitors at detecting clinically significant arrhythmias.*

* Utility of Mobile Outpatient Telemetry." *The Journal of Cardiovascular Electrophysiology*, Vol. 18, No. 3, March 2007.

In March 2007, CardioNet announced the completion of its acquisition of PDSHeart, Inc., a leading provider of cardiac monitoring services. It provides physician-prescribed remote and ambulatory care monitoring of asymptomatic and symptomatic arrhythmia detection via landline, cellular telephone and the Internet. PDSHeart's WebHolter® is the industry's first Web-based digital Holter monitoring system. PDSHeart provides monitoring services to approximately 150,000 patients in 49 US states. Terms of the acquisition were not disclosed. PDSHeart operates as a subsidiary of CardioNet.

In December 2010, CardioNet announced the completion of its acquisition of Biotel, inc., a leading company in the development, manufacture, testing and marketing of medical devices and related software products.

CardioNet has raised venture capital funding, and investors include: Hambrecht & Quist Capital Management, Sanderling Ventures, IngleWood Ventures, BioFrontier Partners, IDEO, Boston Scientific, and Foundation Medical Partners. In March 2008, CardioNet announced an initial public offering.

CardioNet: Detecting and Transmitting Arrhythmias Automatically

With CardioNet, physician-specified cardiac rhythm problems can be quickly identified, quantified, and communicated to the prescribing physician. CardioNet automatically detects and transmits arrhythmic events without any patient interaction – an important advantage since many arrhythmic events are symptom-free.

The CardioNet System is comprised of a sensor, monitor, and base:

- The lightweight sensor is worn by the patient on a neck strap or belt clip as it continuously detects and transmits an electrocardiogram (ECG) to the monitor.
- The monitor analyzes the patient's ECG in real time, heartbeat by heartbeat, at home or away, as it's transmitted from the sensor. When an abnormal rhythm is identified, the data are automatically sent to the CardioNet Monitoring Center where trained technicians review, respond, and report the information as needed.
- If an arrhythmic event occurs when the patient is home and the monitor is in the base, the normal telephone line transmits the data. Away from home, the monitor uses an embedded cell phone to transmit the data.

CardioNet provides the referring physician with daily reports of significant cardiac events, analysis and symptoms by fax or online via the Internet. When critical cardiac events occur, the monitoring center sends urgent reports to the physician and, when appropriate, contacts emergency services.

Mission Statement, Vision, and Values

Mission:

Providing better information to improve human health

Vision:

To be the world leader in wireless medicine and the delivery of health information by providing products and services that will improve quality of life and reduce cost of care

Values:

- We will create an environment that inspires creativity, innovation and personal growth
- We will treat each other with respect and dignity
- We will deliver the highest possible quality/value proposition to patients, physicians, other care providers, and payors
- We will grow profitably at a rate faster than the markets in selected segments
- We will always operate in a highly ethical and legally compliant fashion

Company Milestones

- | | |
|------|---|
| 2011 | CardioNet surpasses 500,000 patients monitored |
| 2010 | CardioNet acquires Biotel, Inc. |
| 2008 | CardioNet initial public offering |
| 2007 | CardioNet acquires Holter and event monitoring company PDSHeart, Inc; “The Diagnosis of Cardiac Arrhythmias” clinical trial results published in <i>The Journal of Cardiovascular Electrophysiology</i> |
| 2002 | FDA marketing clearance for CardioNet Ambulatory Monitor; Patient monitoring service center opens in Philadelphia, PA |
| 1999 | CardioNet founded in San Diego, CA |

Management Team

Joseph Capper, President and CEO

Heather Getz, CPA, CFO

Andy Broadway, VP, Marketing

Peter Ferola, General Counsel and SVP, Corporate Development

Charles Gropper, SVP, Research and Development

George Hrenko, SVP, Human Resources and Organizational Excellence

Jareer Kasrawi, SVP, Strategic Contracts

Anna McNamara, RN, SVP, Clinical Operations

Anthony Schuler, SVP, Sales

Dan Wisniewski, SVP, Business Operations

Contact Information

For additional information, contact:

Investor Relations

1.800.908.7103

investorrelations@cardionet.com

www.cardionet.com

CardioNet Corporate Offices & Monitoring Center

227 Washington Street, Suite 300

Conshohocken, Pennsylvania 19428

Telephone (610) 729-7000

Fax (610) 828-8048

###